Country: Kanada
Lingwa: Ingliż
Sors: Health Canada
CLOTRIMAZOLE
TARO PHARMACEUTICALS INC
G01AF02
CLOTRIMAZOLE
1%
CREAM
CLOTRIMAZOLE 1%
VAGINAL
50GM
OTC
AZOLES
Active ingredient group (AIG) number: 0110231001; AHFS:
APPROVED
2020-02-21
_PAGE 1 OF 22_ _ _ _CLOTRIMADERM VAGINAL 6 _ _CLOTRIMADERM VAGINAL 3 _ _CLOTRIMADERM EXTERNAL CREAM _ PRODUCT MO N OG RA PH CLOTRIMADERM VAGINAL 6 (Clotrimazo le Vaginal Cream USP 1%) CLOTRIMADERM VAGINAL 3 (Clotrimazo le Vaginal Cream USP 2%) CLOTRIMADERM EXTERNAL C RE AM (Clotrimazole Vaginal Cream USP 1%) ANTIFUNGAL AG E NT Taro Pharmaceuticals Inc. Date of Revision: 130 East Drive April 29, 2022 Brampton, Ontario L6T 1C1 CONTROL #263252 _PAGE 2 OF 22_ _ _ _CLOTRIMADERM VAGINAL 6 _ _CLOTRIMADERM VAGINAL 3 _ _CLOTRIMADERM EXTERNAL CREAM _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................................... 3 CONTRAINDICATIONS ............................................................................................................. 3 WARNINGS AND PRECAUTIONS............................................................................................. 3 ADVERSE REACTIONS ............................................................................................................. 4 DRUG INTERACTIONS .............................................................................................................. 5 DOSAGE AND ADMINISTRATION........................................................................................... 6 OVERDOSAGE ............................................................................................................................ 6 ACTION AND CLINICAL PHARMACOLOGY ...................................................................... 6 STORAGE AND STABILITY....................................................................................................... 8 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................................. 8 PART II: SCIENTIFIC INFORMATION .... Aqra d-dokument sħiħ